Germany – Pharmaceutical products – Abschluss einer nicht-exklusiven Rabattvereinbarung nach § 130a Abs. 8 SGB V zum Wirkstoff Formoterol (ausschl. Dafo. DOS), ATC R03AC13 für die Zeit 01.07.26 - 30.06.28 (zzgl. V.-Option 1x12 Monate)

Section 130a, paragraph 8, of the German Social Code (SGB V) allows health insurers and pharmaceutical companies to conclude framework discount contracts for medicines to be dispensed at the expense of the statutory health insurers. With regard to the relevant legal provisions for the award of public contracts, the DAK-Gesundheit regularly conducts substance-related, formal tendering procedures in accordance with the regulations of Part 4 of the German Competition Act (GWB). For medicines to be specified by the bidder in more detail in Annex 2 to the contract, containing the substance Formoterol (exclusively in the DOS dosage form), ATC R03AC13, the DAK-Gesundheit intends to conclude medicines discount contracts with as many interested pharmaceutical companies as possible until new medicines discount contracts come into force. A discount contract under the approval model for the aforementioned substance will come into force for the first time on 01.07.2026 and will end on 30.06.2028 (plus extension option 1x12 months). It will automatically end, regardless, with the entry into force of the exclusive contract.